|
Terumo Interventional Systems Announces Launch of Glidewire Advantage™ Peripheral Guidewire
Wire Provides Value-Added Benefit to Industry Leading Wire Technology
|
 |
Glidewire
Advantage™
Peripheral Guidewire |
|
September
13, 2009 -- Somerset, New Jersey -- Terumo Interventional
Systems has announced the launch of its Glidewire Advantage™ Peripheral
Guidewire, a single wire that enables the operator to both
cross the lesion and deliver interventional devices such
as balloons and stents. The Glidewire Advantage is based
upon Terumo’s “gold-standard” Glidewire® technology.
The Glidewire Advantage Peripheral Guidewire combines Terumo’s
well-established Glidewire construction on the distal 25 cm
with a unique spiral PTFE coating on the proximal end. The result
is a guidewire that easily navigates and crosses the lesion,
while also providing the operator with excellent tactile feel
and support for secure device placement. These two wire sections
are seamlessly fused together using Terumo’s proprietary DuoCore™ Technology. |
"On selected cases, this may be the only
wire we use,” said Vikram S. Kashyap,
M.D., Associate Professor of Surgery, Department of Vascular Surgery, Cleveland
Clinic Lerner College of Medicine. “Thus,
access, sheath placement and intervention can be performed using this
and negating two or three other wire choices.”
Terumo’s Glidewire product line, manufactured directly by Terumo for
more than 20 years, has long been viewed as the “gold standard” in
hydrophilic guidewires. The Glidewire Advantage is Terumo’s response
to physicians’ desire
to shorten procedure time, improve efficiencies and deliver better
patient outcomes.
“ The Glidewire Advantage builds on our industry leading Glidewire technology
by providing the Endovascular Specialists with a wire that delivers Glidewire
performance with the additional benefit of proximal control and support; this
is one wire capable of performing two jobs,” said Susan Anderson, Marketing Manager,
Lesion Access. “The
one-wire approach has the potential to shorten procedure and fluoroscopy
times, as well as reduce the risk of complications that could be associated
with multiple wire exchanges.”
For more information, customers can contact Terumo Interventional Systems
by calling its Inside Sales Customer Care Team at 800.862.4143 or by
visiting http://www.terumois.com.
Terumo Interventional Systems
Terumo Interventional Systems (TIS), a strategic business unit of Terumo Medical
Corporation, directly markets a full line of guidewires, catheters, introducer
sheaths, guiding sheaths and embolization products for use in a multitude of
different interventional procedures.
Interventional Radiologists, Interventional Neuroradiologists, Interventional
Cardiologists, and Vascular Surgeons are among the medical professionals that
depend upon TIS products to access and cross difficult-to-reach lesions, thereby
allowing therapeutic intervention in previously unreachable vascular beds.
Terumo Medical Corporation
Founded in 1972 as a Terumo Corporation subsidiary, Terumo Medical Corporation
(TMC) develops, manufactures, and markets high-quality medical devices used in
a broad range of applications in numerous healthcare markets. TMC manufactures
a broad portfolio of needles and syringes, entry-site management products, and
a line of sterile connection devices used in hospitals and blood banks worldwide.
Terumo Corporation
Tokyo-based Terumo Corporation is one of the world’s leading medical device manufacturers
with $3.0 billion in sales and operations in more than 160 nations. Founded in
1921, the company develops, manufactures, and distributes world-class medical
devices including products for use in cardiothoracic surgery, interventional
procedures, and transfusion medicine; the company also manufactures a broad array
of syringe and hypodermic needle products for hospital and physician office use.
Terumo contributes to society by providing valued products and services to the
healthcare market and by responding to the needs of healthcare providers and
the people they serve. Terumo Corporation’s shares are listed on the first section
of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg
4543: JP) and is a component of the Nikkei 225, Japan’s
leading stock index.
Source: Terumo
Interventional Systems
|
